Dalbavancin Safe and Effective for ABSSSI in Patients With SIRS

Dalbavancin efficacy rates were comparable in patients who met and in patients who did not meet SIRS criteria. Photo Credit: Dr P. Marazzi/Science Source.

This article is part of Infectious Disease Advisor’s in-depth coverage of IDWeek 2017™, which took place in San Diego, CA. Our staff will be reporting on the latest treatment advancements and research initiatives for skin infections. Check back regularly for highlights from IDWeek 2017.

Dalbavancin is well tolerated and effective for patients with systemic inflammatory response syndrome (SIRS) and an acute bacterial skin and skin structure infection (ABSSSI), according to study findings presented at IDWeek 2017, held October 4-8 in San Diego, California.

“Treating ABSSSIs in patients with SIRS is challenging,” noted the investigators. “Dalbavancin, a long-acting lipoglycopeptide with potent activity against gram-positive pathogens including methicillin-resistant Staphylococcus aureus, is approved [by the US Food and Drug Administration] as a single- or 2-dose regimen for ABSSSI.”

Researchers evaluated data from a previous double-blind, phase 3, randomized clinical trial that featured patients with SIRS and ABSSSI (n=698).

Of the patients enrolled in the study, a total of 303 (43%) had SIRS. Those who had SIRS had higher inflammatory markers and greater rates of cellulitis compared with those who did not meet the criteria for having SIRS. At 28-day follow-up, patients with vs without SIRS who were diagnosed with an ABSSSI had similar success rates when treated with dalbavancin (91.8% and 92.8%, respectively).

Treatment-emergent adverse events related to dalbavancin therapy were low among those with SIRS and without SIRS (6.3% vs 8.2%, respectively). Serious treatment-emergent adverse events were low and similar across both groups (2.0% vs 1.5%, respectively).

Disclosures: With the exception of Frank LoVecchio, DO, MPH, all authors are employees of Allergan plc.